Testing a combination of two medications to treat severe COVID-19
Establishing the Therapeutic Efficacy of Alpha-1-Antitrypsin and Enoxaparin Against COVID-19
This study is looking at whether using a combination of two medications, alpha-1-antitrypsin and enoxaparin, can help people with severe COVID-19 by fighting the virus and reducing inflammation and blood clots.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Eastern Colorado Health Care System NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10869869 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of combining alpha-1-antitrypsin (AAT) and enoxaparin to treat patients with severe COVID-19. The study aims to demonstrate how this combination can inhibit the virus and reduce inflammation and blood clotting, which are critical issues in severe cases. Using advanced molecular modeling and various biological models, the research seeks to establish a foundation for future clinical trials that could lead to effective therapies for those suffering from severe COVID-19.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing severe symptoms of COVID-19, particularly those at high risk for complications.
Not a fit: Patients with mild COVID-19 symptoms or those who have fully recovered from the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly improves outcomes for patients with severe COVID-19.
How similar studies have performed: While the combination of AAT and enoxaparin has not been extensively tested together for COVID-19, similar approaches using anti-inflammatory and anti-thrombotic agents have shown promise in other studies.
Where this research is happening
Aurora, UNITED STATES
- VA Eastern Colorado Health Care System — Aurora, United States (Active)
Researchers
- Principal investigator: Chan, Edward D — VA Eastern Colorado Health Care System
- Study coordinator: Chan, Edward D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.